$AKAM today's scanner #PreMarketMover

Cloud computing company Akamai saw stocks pop after it reported earnings and revenue that beat analysts' expectations. The enterprise software company posted earnings of 72 cents per share on revenue of $579 million, excluding items, better than the 62 cents on $569 million expected by Wall Street.

Akamai Technologies (NASDAQ: AKAM) reported Q4 EPS of $0.72, $0.10 better than the analyst estimate of $0.62. Revenue for the quarter came in at $579 million versus the consensus estimate of $560.72 million.

The Company also announces today that its Board of Directors has authorized a new $1 billion share repurchase program, effective from February 9, 2016 through December 31, 2018. The Company's goal for this program is to offset the dilution created by its employee equity compensation programs and provide the flexibility to increase its capital distributions to shareholders as business and market conditions warrant.



SEE ALSO: Wednesday's Scanner

$APOL today's scanner on #NEWS taken private in $1.1 billion deal #PreMarketGainers @ $8.82 UP 27% TP @ $9.50's

Apollo Education Group Inc. said Monday it had reached a deal to be taken private by a group of investors including Apollo Global Management LLC in a $1.1 billion deal, as the struggling education company attempts to overhaul its University of Phoenix operations.



SEE ALSO: Monday's Scanner

$BSI today's scanner on Acquisition Offer #NEWS #PreMarketGainers @ $4.35 UP 19%

Alon Blue Square Announces Receipt of Offer for Acquisition of Control of the Company

Alon Blue Square Israel Ltd. (BSI) (the "Company") announced today that it received an offer pursuant to which a company in the Zeevi Group would acquire 51% of the Company's outstanding shares from Alon Retail Ltd., a major Company shareholder, for NIS 85 million. In addition, the purchaser would obtain a three year option to acquire an additional 21% of the Company's shares from Alon Retail at the same price per share.

$MFLX today's scanner Buyout #NEWS #PreMarketGainers @ $23.00 UP 40%

Chinese manufacturing conglomerate Suzhou Dongshan Precision Manufacturing Co. agreed to buy Multi-Fineline Electronix Inc. for $610 million.

$GLUU #NEWS: on Profits From Kardashian Game

Partnership With Taylor Swift today's scanner #PreMarketGainers @ $2.44 UP 22% technically Resistance @ $2.45 with price target @ $2.60 Goal 7%

Glu Mobile Inc. (NASDAQ:GLUU) shares were up almost 28% during after-hours trading yesterday. The stock surge came after the mobile game company reported upbeat fourth-quarter fiscal year 2015 (4QFY15) earnings results and a multi-year partnership with Taylor Swift.

Why $AXLL is UP 71% #PreMarketGainers @ $16.75 ?

Westlake Chemical Corporation (NYSE: WLK) announced tday that it has submitted a proposal to acquire all of the outstanding shares of Axiall Corporation (NYSE: AXLL) for $20.00 per share (comprised of $11.00 in cash and 0.1967 of a Westlake share, which represented a value of $9.00 based on Westlake's closing price on January 22, 2016, the last trading day before Westlake made its proposal).

Why $GIMO is UP 16% #AfterHoursGainers @ $25.75 ?

Gigamon Inc (NASDAQ:GIMO) announced its quarterly earnings results on Thursday. The company reported $0.29 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.06, Market Beat reports. The company earned $67 million during the quarter, compared to analysts’ expectations of $62.76 million. During the same period last year, the firm earned $0.18 earnings per share. Gigamon’s revenue for the quarter was up 30.8% on a year-over-year basis.

Why $AMDA is UP 30% #Realtime @ $2.50 ?

SALT LAKE CITY, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurring March 5-8, 2016 in Orlando, Florida.  

$UA Revenue Rises 31% #BeforeBell @ $77.25 UP 13%

Under Armour UA +1.47% profit and revenue surged in the fourth quarter, propelled by growing footwear sales, and prompting the company to offer a better-than-expected outlook.

Investors cheered the strong results and sent shares up 14% in pre-market trading.

Why $NEOS is UP 60% #PreMarketGainers @ $15.00 ?

DALLAS and FORT WORTH, Texas, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that the U.S. Food and Drug Administration (FDA) approved Adzenys XR-ODT™ for the treatment of ADHD in patients six years and older. With this approval, Adzenys XR-ODT is the first and only extended-release orally disintegrating tablet (ODT) for the treatment of ADHD.

Why $RWLK is UP 14% #AfterHoursGainers @ $11.00 ?

Wall Street consensus is expecting that ReWalk Robotics Ltd (NASDAQ:RWLK) will report earnings of $-0.56 per share when the firm next issues their quarterly results. According to Zacks, the firm should release their report on or around 2016-02-11. This is based on the latest information available.

Why $FCX is UP 11% #Realtime @ $4.65 ?

NEW YORK (TheStreet) --Freeport-McMoRan (FCX -Get Report) stock is soaring by 16.79% to $4.91 in afternoon trading on Wednesday after pledging to reduce a debt load that exceeded $20 billion in the third quarter.

Why $FATE is UP 17% #PreMarketGainers @ $2.90 ?

Fate Therapeutics, Inc. (NASDAQ: FATE) announced today the U.S. Food and Drug Administration (FDA) has cleared the Company's investigational new drug (IND) application for ProTmune, a programmed cellular immunotherapy consisting of donor-sourced mobilized peripheral blood cells which have been functionally modulated using two small molecules. The IND is now active and Fate Therapeutics plans to initiate a multi-center, randomized, controlled Phase 1/2 clinical trial in adult patients with hematologic malignancies undergoing mobilized peripheral blood (mPB) hematopoietic cell transplantation (HCT) in mid-2016.

Why $CETX is UP 15% #BeforeBell @ $2.59 ?

FARMINGDALE, N.Y., Jan. 26, 2016 /PRNewswire/ -- Cemtrex (CETX), a diversified industrial and manufacturing leader, announced today that the company has received new orders in excess of $8 Million over the last two months across its Industrial Products and Services Group and Electronics Manufacturing Services Group.

Why $FMER is UP 24% #PreMarketGainers @ $19.00 ?

Huntington Bancshares Inc (HBAN.O) said on Tuesday it has agreed to buy Ohio-based FirstMerit Corp (FMER.O) for about $3.4 billion in a cash-and-stock deal.

Huntington expects the deal, which would combine two of Ohio's midsize banks, to add to its earnings per share in 2017, excluding one-time merger-related expenses.

Why $EVOL is UP 8% #PreMarketGainers @ $5.55 ?

ENGLEWOOD, CO--(Marketwired - Jan 26, 2016) - Evolving Systems, Inc. (NASDAQ: EVOL), a leader in real-time activation, analytics and marketing for connected mobile devices, today announced that another wireless operator in Africa has selected the Company's Dynamic SIM Allocation™ (DSA) solution. The operator is part of a major multinational telecom group, and this is Evolving Systems' seventh order within the group.

Why $S is UP 15% #PreMarketGainers @ $2.90 ?

Sprint Corp. (NYSE: S) reported Q3 EPS of ($0.21), versus ($0.60) reported last year. Revenue for the quarter came in at $8.1 billion versus the consensus estimate of $8.69 billion.

Adjusting for the aforementioned severance and exit costs and impairment charge, net loss would have improved by approximately $300 million year-over-year, or $0.08 per share.

Why $PETX is UP 12% #AfterHoursGainers @ $3.55 ?

LEAWOOD, Kan., Jan. 25, 2016 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company filed an administrative New Animal Drug Application (NADA) with the Food and Drug Administration's Center for Veterinary Medicine (CVM) for Galliprant® for the control of pain and inflammation in dogs with osteoarthritis. The Animal Drug User Fee Act (ADUFA) date for approval is set for March 25. Aratana anticipates commercial availability of Galliprant to veterinarians in fall 2016.

Why $RLYP is UP 10% #AfterHoursGainers @ $21.50 ?

Relypsa, Inc. (NASDAQ: RLYP) announced results from 12 Phase 1 studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa for oral suspension and 12 drugs that had previously demonstrated binding in in vitro tests. When Veltassa was administered at the same time as the drugs being tested, there was no clinically meaningful reduction in absorption for nine of the 12 drugs. Three drugs showed reduced absorption when they were co-administered with Veltassa, however, when dosing of Veltassa and these drugs was separated by three hours, no reduction in absorption was observed.

#NEWS: Why $WPZ was UP 4% @ $22.14 ?

Shares of Williams Partners L.P. (NYSE:WPZ) saw unusually-strong trading volume on Monday following a dividend announcement from the company,AnalystRatings.NET reports. Approximately 3,539,725 shares were traded during mid-day trading, a decline of 10% from the previous session’s volume of 3,927,790 shares.The stock last traded at $23.27 and had previously closed at $21.45.